NeVa
Commercial- Indications
- Acute ischemic stroke
Company intelligence / Profile preview
Vesalio’s proprietary mechanical thrombectomy platforms—NeVa™, enVast™, and pVasc™—are designed to remove all types of blood clots from neurovascular, coronary, and peripheral vessels. The company reports over 12,000 patients treated globally across more than 50 countries. Clinical results highlight first-pass recanalization success rates with NeVa™ in acute ischemic stroke and positive early feedback on pVasc’s efficacy in challenging cases of acute limb ischemia. Enrollment is ongoing or recently completed for key U.S. IDE studies.
4 more assets in the full pipeline.
Request access →Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Vesalio.